Immunosuppressants - Croatia

Croatia

The Immunosuppressants market in Croatia is forecasted to achieve a revenue of US$13.37m units in 2024.
This market is expected to exhibit a compound annual growth rate (CAGR 2024-2029) of 14.89%, leading to a market volume of US$26.76m units by 2029.
When compared globally, United States is projected to generate the highest revenue in this market, amounting to US$35,470.00m units in 2024.
Croatia's immunosuppressant market is experiencing a surge in demand due to the increasing prevalence of autoimmune diseases in the population.

Key regions: Australia, Germany, United Kingdom, United States, France

Market

Region

Region comparison

Currency

Analyst Opinion

The Immunosuppressants market in Croatia has been steadily growing in recent years.

Customer preferences: Croatia has a high prevalence of autoimmune diseases, which has led to an increase in demand for immunosuppressants. Patients in Croatia tend to prefer generic drugs due to their lower cost, which has resulted in a rise in the production and consumption of generic immunosuppressants.

Trends in the market: The Croatian government has been implementing measures to increase the availability of immunosuppressants in the country. This has led to an increase in the number of pharmacies that stock these drugs, making them more accessible to patients. Furthermore, there has been a trend towards the use of biosimilars in Croatia. Biosimilars are cheaper alternatives to biologic drugs and have been gaining popularity in recent years.

Local special circumstances: Croatia has a universal healthcare system, which means that the government is the main purchaser of drugs in the country. This has led to the implementation of cost-containment measures, such as the use of generic drugs, which has affected the immunosuppressants market. Additionally, Croatia is a member of the European Union, which has led to the harmonization of drug regulations and the adoption of EU pricing policies.

Underlying macroeconomic factors: The Croatian economy has been growing in recent years, which has led to an increase in healthcare spending. This has allowed the government to invest more in the healthcare system and increase the availability of drugs, including immunosuppressants. Additionally, the aging population in Croatia has led to an increase in the prevalence of autoimmune diseases, which has driven demand for immunosuppressants.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.